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Abstract
Background Gastroschisis (GS) is a congenital abdomi-
nal wall defect that results in the development of GS-
related intestinal dysfunction (GRID). Transforming
growth factor-b, a pro-inflammatory cytokine, has been
shown to cause organ dysfunction through alterations in
vascular and airway smooth muscle. The purpose of this
study was to evaluate the effects of TGF-b3 on intestinal
smooth muscle function and contractile gene expression.
Methods Archived human intestinal tissue was analyzed
using immunohistochemistry and RT-PCR for TGF-b iso-
forms and markers of smooth muscle gene and micro-RNA
contractile phenotype. Intestinal motility was measured in
neonatal rats ± TGF-b3 (0.2 and 1 mg/kg). Human intes-
tinal smooth muscle cells (hiSMCs) were incubated with
fetal bovine serum ±100 ng/ml of TGF-b 3 isoforms for 6,
24 and 72 h. The effects of TGF-b3 on motility, hiSMC
contractility and hiSMC contractile phenotype gene and
micro-RNA expression were measured using transit, col-
lagen gel contraction assay and RT-PCR analysis. Data are
expressed as mean ± SEM, ANOVA (n = 6–7/group).
Results GS infants had increased immunostaining of
TGF-b3 and elevated levels of micro-RNA 143 & 145 in
the intestinal smooth muscle. Rats had significantly
decreased intestinal transit when exposed to TGF-b3 in a
dose-dependent manner compared with Sham animals.
TGF-b3 significantly increased hiSMC gel contraction and
contractile protein gene and micro-RNA expression.
Conclusion TGF-b3 contributed to intestinal dysfunction
at the organ level, increased contraction at the cellular level
and elevated contractile gene expression at the molecular
level. A hyper-contractile response may play a role in the
persistent intestinal dysfunction seen in GRID.
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Introduction
Gastroschisis (GS) is the leading cause of pediatric intes-
tinal failure and intestinal transplantation. GS intestinal
injury results in edema, ileus, failure of intestinal defense
mechanisms and severe intestinal dysfunction. GS-related
intestinal dysfunction (GRID) delays full enteral autonomy
and increases morbidity that is associated with prolonged
hospital stays [1–3].
Normal intestinal motility is regulated by active and
passive mechanical properties. Active mechanical prop-
erties include smooth muscle tone, phasic contractility
and luminal fluid flow [4]. Smooth muscle tone is
important in the initiation and maintenance of peristalsis
and propagation of food content [5]. Smooth muscle
hypertrophy, collagen deposition and delayed smooth
muscle maturity are characteristics of GS intestinal injury,
and some studies suggest that these characteristics alter
the active mechanical properties which may result in
GRID [1, 6, 7].
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Two risk factors for GRID development have been
identified in humans and animal models: (1) the mesenteric
constriction of GS abdominal wall defect and (2) intestinal
exposure to amniotic fluid (AF). Based on these risk fac-
tors, we developed a postnatal rat model to study whether
the mechanical influence of the abdominal wall defect
would cause GRID [8]. We found simulating the abdomi-
nal wall defect elevated the mesenteric venous pressure
producing non-occlusive mesenteric venous hypertension
(NMH). NMH without the presence of AF contributed to
intestinal dysmotility, smooth muscle hypertrophy and
bowel shortening recreating GRID in our model.
Pro-inflammatory mediators have been shown to impair
intestinal motility in a variety of settings in animal models.
Our model also provided evidence that NMH produced
intestinal inflammation [9–12]. Transforming growth fac-
tor-beta (TGF-b), an inflammatory cytokine, has been
associated with a number of human smooth muscle dis-
eases such as asthma and atherosclerosis. These disorders
exhibit smooth muscle migration, hypertrophy, hyperpla-
sia, extracellular matrix deposition and inflammation as a
part of end-organ remodeling and dysfunction, a charac-
teristic shared with GRID. Using cDNA microarray, we
found that the intestine in NMH animals had increased
gene expression of TGF-b proteins and receptors. We
confirmed this finding by staining the intestine for TGF-b
proteins and found that the intestinal smooth muscle cells
had increased levels of TGF-b3 (unpublished data). Since
limited data exist on TGF-b30s role in the intestine, we
hypothesized that TGF-b3 is an important signal for
intestinal smooth muscle dysfunction promoting the GRID
phenotype.
Materials and Methods
The University of Texas Animal Welfare Committee
approved all procedures according to the National Insti-
tutes of Health Guide for the Care and Use of Laboratory
Animals. The University of Texas Institutional Review
Board approved all human studies performed in this study.
Reagents and Devices
The following cells and reagents were used in our experi-
ments: Sprague–Dawley rats (Harlan Labs, Indianapolis,
Indiana, USA), human intestinal smooth muscle cells
(hiSMC, ScienCell), smooth muscle cell medium (FBS,
ScienCell), Dulbecco’s phosphate-buffered saline (DPBS,
Thermo Scientific), human TGF beta 1 and TGF beta 2
(TGF-b1 & b2 (100 ng/ml), Biolegend) and TGF-b3
(TGF-b3 (100 ng/ml), Prospec) recombinant proteins,
rabbit polyclonal antibody to all TGF-bs (Abcam), mouse
monoclonal antibody a-smooth muscle actin (a-SMA,
Abcam), cell dissociation solution (Mediatech, 25-056CI),
Alexa Fluor goat anti-mouse IgG (H ? L) highly cross-
adsorbed secondary antibody (Life technologies), Alexa
Fluor goat anti-rabbit IgG (H ? L) highly cross-adsorbed
secondary antibody (Life technologies), 4’,6-diamidino-2-
phenylindole (DAPI, Life technologies) and rat tail colla-
gen I (BD Biosciences). Western blot signals were detected
by using Kodak image station 4000R. Micro-RNA mate-
rials included: miRNeasy FFPE and miScript II RT kits
(Qiagen) and miRNA assays (SA Biosciences, Valencia,
CA).
TGF-b Isoform Immunohistochemistry
Human Intestinal Tissue We obtained archived intestinal
tissue samples from infants with GS that underwent sur-
gical resection secondary intestinal atresia. GS infants that
had intestinal volvulus or perforation and/or necrotic seg-
ments were excluded from evaluation. We used intestinal
tissue from age-matched infants that died without intestinal
pathology for our control tissue. We evaluated the
pathologist’s autopsy reports to determine whether the
tissue sections were taken from healthy intestinal tissue
segments. After deparaffinization and antigen recovery,
slides were incubated at 4 C overnight with a primary
TGF-b1, 2 or 3 antibody and co-stained with a-actin
antibody. The slides were then incubated for 1 h with a PE-
conjugated fluorescent secondary antibody. The slides were
then stained with DAPI for nuclear visualization, and 2D
deconvolution microscopy was utilized to visualize TGF-b
isoforms and a-actin localization staining.
Functional Studies
Determination of Smooth Muscle Contractility in Cell
Culture
Primary hISMCs were suspended (500,000 cells/mL) in a
rat tail collagen I solution (2 mg/mL), and FBS was added
to the diluent. 1 N NaOH 0.023 9 collagen stock volume
was used to adjust pH to neutral immediately after cells
were added. TGF-b1, 2 or 3 was added to the mixture. A
250 ll cell suspension was dispensed into a 48-well plate.
The collagen gel was allowed to solidify at 37 C for
30 min. After loosening the gel from each well, we added
250 ll FBS ± TGF-b1, 2 or 3 to the wells and imaged the
gels using a Kodak image station 4000R at 6, 24 and 72 h.
Determination of Intestinal Transit in Rats
Male neonatal Sprague–Dawley rats, weighing between 40
and 60 g, were fasted 10–12 h prior intraperitoneal (i.p.)
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injection of low dose (0.2 mg/kg) or high dose (1 mg/kg)
of recombinant TGF-b3 protein. Intestinal transit was
measured at 12 h after i.p. injection of TGF-b3 according
to our previously published methods [8]. Intestinal transit is
determined by the distribution of a non-absorbable 70-kDa
fluorescein isothiocyanate-labeled dextran (FD70). Briefly,
200 lL of 2.5 mg/ml solution (dissolved in distilled water)
was administered by oral gavage. After 60 min, the
supernatant from the effluent from the intestinal segments
was collected and assessed fluorometrically for concen-
tration of FD70. Transit was evaluated by calculating the
geometric center of distribution of FD70 (
P
((fluorescent
signal per segment (percent) 9 segment number)/100).
Gene Expression Studies
Cell Culture Techniques Human intestinal smooth mus-
cle cells were maintained in DMEM supplemented with
10 % fetal bovine serum at 37 C in a humidified atmo-
sphere of 5 % CO2. Early passage cells (passage 1–3) were
used. Cells were grown to 90 % confluence in DMEM-
10 % fetal bovine serum ± TGF-b3 at 6, 24 and 72 h. The
cells were harvested for the isolation of total RNA (con-
tractile/synthetic phenotype expression) and miRNA
(remodeling phenotype expression) using a commercially
available kit.
Laser Capture Microdissection Microscopy We obtained
archived intestinal tissue samples from patients that with
Gastroschisis (GS), intestinal atresia (IA), necrotizing
enterocolitis (NEC) and age-matched premature infant
control tissue. We added the IA and NEC groups secondary
to the method used to calculate miRNA-143/145 expres-
sion. The age-matched controls were used as our control
reference. We used these samples to perform the laser
capture microdissection (LCM) of the small intestine
smooth muscle layer. Separate sections of formalin-fixed
paraffin-embedded specimens were oriented to provide cut
sections parallel with the longitudinal axis of the bowel.
Ten micrometer tissue slices were mounted and stained
with H&E. Five slides per human sample were used. The
slides were then deparrafinized with xylene and graded
concentrations of ethanol. The Applied Biosystems Arc-
turusXTTM Laser Capture Microdissection System was
used for laser capture and operated as instructed by the
manufacturer. This is a unique combination of infrared (IR)
laser-enabled LCM and ultraviolet laser cutting in one
platform used for the isolation of specific cell types from
heterogeneous tissue samples. We isolated the muscularis
mucosae and muscularis externa alone from the small
intestine. The cells were transferred to a polymer film
(CapSure HS LCM Caps). After collecting the cells of
interest, the samples were processed immediately for
microRNA (miRNA) isolation and analysis using the
miRNeasy FFPE kits.
Contractile and Synthetic Phenotypic Determination
in Gastroschisis and Human Intestinal Smooth Muscle
Cell Culture
Gene-specific primers and target-specific miRNA assays to
determine contractile versus synthetic gene expression were
adapted from the vascular smooth muscle literature [13, 14]
and are listed in Table 1. Real-time quantitative polymerase
chain reaction (RT-PCR) using SYBR Green was per-
formed to monitor changes in messenger RNA (mRNA)
gene expression from our human intestinal smooth muscle
cell culture at 6, 24 and 72 h. Relative mRNA expression
ratios were normalized to human GAPDH and expressed as
a fold change compared with 6-h sample.
miRNA isolated from cell culture and LCM-captured
muscularis was re-suspended in RNase-free H2O and then
analyzed using the Agilent 2100 bioanalyzer to assess the
integrity of total RNA. Once the samples were identified to
have viable RNA, we reverse-transcribed the total RNA
containing miRNA using the miScript II RT kit. The reac-
tions were then loaded onto an Eppendorf Mastercycler
personal using conditions provided in the manual. This
resulted in the conversion of mature miRNAs into cDNA.
Equal amounts of cDNA were used for subsequent poly-
merase chain reaction (PCR). Since there are no validated
reference genes for miRNA qPCR in GS, we used RNU6-2
as control for the normalization of miRNA expression [15,
16]. Samples from each subject with primers for the target
and reference genes were loaded separately in triplicates in a
96-well plate. StepOnePlusTM Real-Time PCR System was
used. At the end of the PCR run, a melting curve analysis
was also performed using miScript SYBR Green PCR Kit






Actin, gamma 2, smooth
muscle, enteric (ACTG2)
NM_001615
Calponin 1, basic, smooth
muscle (CNN1)
NM_001299












Myosin, heavy chain 11,
smooth muscle (MYH11)
NM_022844
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by Qiagen, using cDNA prepared in the previous reverse
transcription to verify purity. We used our age-matched
controls as the control sample to perform our DDCt calcu-
lations. The intestinal atresia and necrotizing enterocolitis
groups served as our comparison groups to determine
whether miRNA-143/145 expression was elevated in GS.
Relative quantification was performed with the data from the
PCR instrument. We decided to use the comparative method
of relative quantification (DDCt method), which relies on
comparing differences in Ct values. Before using this
method, a validation experiment was performed to make
sure that the amplification efficiencies of both target and
reference are comparable.
Data Analysis
All data are expressed as mean ? SEM using a commer-
cial statistical software program (NCSS, Kaysville, UT).
Statistical significance of differences among groups was
determined by either a Student’s t test or analysis of vari-
ance (ANOVA) followed by Duncan’s and Tukey–Kramer
multiple comparison tests where applicable. A p value
\0.05 was considered significant (n = 4–6).
Results
Expression of TGF-b Isoforms in Human Intestinal
Smooth Muscle in Infants with GS
To investigate our hypothesis that intestinal smooth muscle
cells were capable of expressing TGF-b3 in GRID, we
stained intestinal tissue from human GS infants for all TGF-
b isoforms. TGF-b3 immunostaining (pixel units: control—
2,324,004 ± 382,219 and GS—4,801,475 ± 330,388*) was
significantly increased compared with TGF-b1 and 2 in GS
Fig. 1 Expression of TGF-b isoforms in the intestinal smooth muscle.
a Calculated mean pixel units of TGF-b1, 2 and 3 from intestinal
tissue sections of human infants with gastroschisis (GS) and premature
infant controls, expressed as mean ± SEM. Groups were compared by
a Student’s t test for each TGF-b group. b Representative photomi-
crographs (magnification 920) from intestinal tissue sections of
human infants with gastroschisis (GS) and premature infant controls
are depicted and show the immunoreactivity of TGF-b3 (green) and
a-actin (red) in the intestinal smooth muscle layers of the intestine.
Co-localization of TGF-b3 and a-actin (yellow) is also seen in the
intestinal smooth muscle layer of GS infant intestine (n = 7)
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infants compared with controls. Compared with control
infants, TGF-b3 and a-actin (Fig. 1b) co-localized to the
intestinal smooth muscle cells in infants with GS.
TGF-b3 Promotes Collagen Gel Contraction
in Intestinal Smooth Muscle Cells
To explain the intestinal smooth muscle dysfunction seen
in GRID, we hypothesized that TGF-b3 signals intestinal
smooth muscle cell hyper-contractility. To determine
whether TGF-b3 promotes cell contractility, we used a
collagen gel matrix assay to measure intestinal smooth
muscle cell contraction. As depicted in Fig. 2a, TGF-b3
contributed to more gel contraction compared with TGF-b1
or 2 (p = 0.001). At 24 h, TGF-b3 caused a 249 %
(p = 0.008) increase in gel contraction compared with
cells not exposed to TGF-b3 (Fig. 2b). By 72 h, TGF-b3
continued to cause intestinal smooth muscle cell contrac-
tion at a 99 % increase over cells not exposed to TGF-b3
(p = 0.005).
TGF-b3 Promotes Intestinal Dysmotility
Next, we investigated the dose-dependent effects of TGF-
b3 on intestinal motility in rats using FITC-Dextran
intestinal transit. The data depicted in Fig. 3 demonstrate
that the average mean geometric center (MGC) in high-
dose TGF-b3 rats (6.7 ± 0.2**, p\ 0.05) was signifi-
cantly decreased compared with Sham (9.0 ± 0.1) and
low-dose TGF-b3 (8.0 ± 0.3*) rats. Low-dose TGF-b3
rats had significantly decreased intestinal transit compared
with Sham rats (p\ 0.05).
TGF-b3 Up-Regulates the Contractile Phenotypic Gene
Expression in Intestinal Smooth Muscle Tissue and Cell
Culture
Because miRNA is known to survive the degradation
process that occurs from embedding tissue in paraffin, we
Fig. 2 TGF-b3 promotes increased contraction of the collagen gel
matrix. a Line diagrams show cell contraction in a collagen gel matrix
(mean ± SEM) with FBS ± TGF-b1, 2 or 3 over 6, 24 and 72 h,
respectively. Intestinal smooth muscle cell contraction is significantly
increased in a time-dependent manner on exposure to TGF-b3.
Groups were compared by ANOVA for each TGF-b group at each
time point. b Line diagrams show percentage of cell contraction in a
collagen gel matrix (mean ± SEM) with FBS ± TGF-b3 over 6, 24
and 72 h. Intestinal smooth muscle cells exposed to TGF-b3 became
more contracted as time increased. Experimental groups were
compared by a Student’s t test
Fig. 3 Administration of TGF-b3 into the peritoneal cavity decreases
intestinal motility. Bar diagrams show intestinal transit as the mean
geometric center in the small intestine (mean ± SEM). At 12 h after
i.p. injection of TGF-b3, intestinal transit is significantly impaired in
a dose–response manner in the animals given i.p. TGF-b3. Experi-
mental groups were compared by ANOVA with a Tukey–Kramer test
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used LCM to isolate the intestinal smooth muscle layer
from infants with and without GS. As shown in Fig. 4,
smooth muscle contractile markers miRNA 143 & 145
(Relative miRNA levels l: 12 ± 4* & 19 ± 5*) are ele-
vated in the GS infants compared to infants with Atresia
(relative miRNA levels: 1 ± 0.2* & 2 ± 0.6) and NEC
(relative miRNA levels: 12 ± 0.4* & 5 ± 2). When
intestinal smooth muscle cells are exposed to TGF-b3 in
culture, they also demonstrated a significant increase in the
contractile miRNA markers 143 & 145 (Fig. 5a).
It is known that intestinal smooth muscle cells in culture
over time switch from a contractile to a synthetic pheno-
type. To investigate whether our intestinal smooth muscle
cells underwent this phenotypic gene change after TGF-b3
exposure, we evaluated known contractile and synthetic
smooth muscle markers. Intestinal smooth muscle cells
exposed to TGF-b3 expressed higher contractile protein
markers compared with cells exposed to FBS only
(Fig. 5b). As depicted in Fig. 6, there was no change in the
intestinal smooth muscle cell synthetic gene expression on
exposure to TGF-b3.
Discussion
We previously demonstrated that non-occlusive mesenteric
hypertension (NMH) causes intestinal dysfunction and
inflammation similar to infants with GRID. However, there
is a paucity of reports on the mediators that contribute to
the smooth muscle dysfunction in GRID. In this report, we
show for the first time that the pro-inflammatory cytokine,
TGF-b3, was significantly elevated in the intestinal smooth
muscle layer in human GS compared with control subjects.
Our data further demonstrated that TGF-b3 was associated
with increased intestinal smooth muscle cell contractility,
global intestinal dysfunction and increased smooth muscle
cell markers of contractile gene expression.
The tissue-level biomechanical force from shear stress,
strain or hypertension is known to signal inflammation and
has recently been shown to participate in smooth muscle
remodeling and phenotypic switching [14, 17]. Smooth
muscle migration, hypertrophy and hyperplasia are prom-
inent features in organ remodeling processes after injury in
smooth muscle-related diseases such as asthma and ath-
erosclerosis remodeling [18, 19]. The GS abdominal wall
defect and NMH model (NMH-simulated model of the
abdominal wall defect in animals) are biomechanical forces
that produce mesenteric venous hypertension that results in
intestinal inflammation and dysfunction [1, 8, 20]. In this
report, we provide new evidence that TGF-b3 impairs
intestinal transit in a dose-dependent manner similar to that
seen in infants and our animal model. Our group has pre-
viously demonstrated that NMH contributed to a significant
decrease in intestinal contractility prior to stimulation of
the enteric nervous system with carbachol [8]. The addition
of carbachol resulted in minimal improvement in NMH-
induced intestinal contractile dysfunction. These findings
suggested that NMH may contribute to a primary smooth
muscle dysfunction that impaired transit and contractile
function. Although our NMH model had decreased intes-
tinal contractility that partially recovered, our current cell
culture experiments using TGF-b3 stimulation showed
increased intestinal smooth muscle cell contraction. Gaw-
aziuk et al. [21] reported that TGF-b was responsible for
Fig. 4 Expression of contractile micro-RNA markers in human
intestinal smooth muscle. Calculated mean relative miRNA levels of
miRNA-143 (a) and miRNA-145 (b) from intestinal tissue sections of
human infants with gastroschisis (GS), intestinal atresia (IA),
necrotizing enterocolitis (NEC) and age-matched premature infant
control tissue, expressed as mean ± SEM. Groups were compared by
ANOVA. Intestinal tissue from the GS patients had significantly
elevated levels of miRNA 143 & 145 compared with the other groups
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super-contractile smooth muscle cell states that produced
non-specific hyper-reactivity of airways in asthmatic
patients. In the erectile dysfunction literature, abnormal
contractile events in vascular smooth muscle cells of the
penis produce end-organ dysfunction [22, 23]. Elevated
intestinal smooth muscle cell contraction may explain why
the NMH model exhibited decreased intestinal contractility
without full recovery and decreased intestinal length.
Cellular signaling and regulation of calcium and myosin
light chain kinase are important in generation and main-
tenance of smooth muscle cell contraction [24, 25]. Well-
known signaling pathways that participate in smooth
muscle contraction include RhoA/Rho-kinase and G-pro-
tein-coupled receptor proteins [23, 26]. While a paucity of
data exists on TGF-b3’s role in intestinal smooth muscle
contraction, several studies have demonstrated the ability
of myofibroblasts and smooth muscle cells to express TGF-
b3 [27–29]. Recent data support that TGF-b is capable of
autocrine signaling which has been shown to produce air-
way smooth muscle hyperplasia [30, 31]. Our results show
that TGF-b3 co-localized with smooth muscle actin, which
suggests that the intestinal smooth muscle is capable of
producing TGF-b3. The intestinal smooth muscle cell
could serve as a source of TGF-b3 in the intestinal smooth
muscle layer of GS infants acting in an autocrine/paracrine
fashion to further exacerbate GRID.
In summary, we demonstrated that the TGF-b3 con-
tributed to intestinal dysfunction at the organ level,
increased contraction at the cellular level and elevated
contractile gene expression at the molecular level. This
hyper-contractile response may play a role in the persistent
intestinal dysfunction seen in GRID.
Fig. 5 TGF-b3 promotes the expression of contractile micro-RNA
markers in human intestinal smooth muscle. a Line diagrams show the
contractile phenotype gene expression (mean ± standard error of the
mean [SEM])) with FBS (a) and FBS ± TGF-b3 (b) over 6, 24 and
72 h. Contractile marker: !-smooth muscle actin (ACTG2), calponin
(CNN1), smooth muscle myosin heavy chain (MYH11) and smooth
muscle-22a (TAGLN). Intestinal smooth muscles exposed to TGF-b3
have a significantly higher expression of contractile genes at all-time
points. These data support that hISMCs exposed to TGF-b3 have a
contractile phenotype
1212 Dig Dis Sci (2015) 60:1206–1214
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